The non-selective cytotoxicity of toxins limits the clinical relevance of the toxins. In recent
years, toxins have been widely used as warheads for antibody‒drug conjugates (ADCs) …

Most patients with advanced prostate cancer (PCa) will develop metastatic castration-
resistant prostate cancer (mCRPC) after androgen deprivation therapy, at this time the tumor …

Maleimides are essential compounds for drug conjugation reactions via thiols to antibodies,
peptides and other targeting units. However, one main drawback is the occurrence of thiol …

Prostate cancer is the second most common type of cancer among men. Its main method of
treatment is chemotherapy, which has a wide range of side effects. One of the solutions to …

Prostate cancer is one of the most commonly diagnosed men's cancers and remains one of
the leading causes of cancer death. The development of approaches to the treatment of this …

Targeted drug delivery for cancer therapy is an emerging area of research. Cancer cells
overexpress certain biomarkers that can be exploited for their targeted therapy. Cyclic cell …

This work describes the enhancement of a novel antitumor therapeutic platform that
combines advantages from small-molecule drug conjugates (SMDCs) and antibody drug …

Hydrophobic payloads incorporated into antibody-drug conjugates (ADCs) typically are
superior to hydrophilic ones in tumor penetration and “bystander killing” upon release from …

Cancer is one of the leading social problems of the modern world. Today prostate cancer is
the second leading cause of cancer deaths among men. Targeted drug delivery is widely …

Simple Summary Prostate-specific membrane antigen (PSMA)-targeting radioligands have
been used clinically to treat metastatic prostate cancer. To deliver a sufficient radiation dose …